Reaction
B-Cell Type Acute Leukaemia reporting signals
As of the last recalculation, B-Cell Type Acute Leukaemia appears in 709 FAERS reports alongside 26 co-occurring drug terms. The strongest observed disproportionality signal is BLINATUMOMAB (PRR 464.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Blinatumomab | 134 | 464.7 | 470.7 |
| Melphalan | 54 | 75.4 | 75.5 |
| Melphalan Hydrochloride | 54 | 68.4 | 68.5 |
| Fludarabine Phosphate | 64 | 52.4 | 52.5 |
| Bortezomib | 104 | 39.8 | 39.9 |
| Lenalidomide | 317 | 39.0 | 39.1 |
| Cyclophosphamide Injection, Solution | 167 | 35.9 | 36.0 |
| Cyclophosphamide | 167 | 35.9 | 36.0 |
| Cyclophosphamide For Injection | 167 | 35.9 | 36.0 |
| Thalidomide | 37 | 31.2 | 31.2 |
| Dexamethasone 1.5 Mg | 191 | 25.8 | 25.8 |
| Dexamethasone | 191 | 25.5 | 25.5 |
| Mesna Injection | 7 | 25.1 | 25.1 |
| Mesna | 7 | 24.6 | 24.7 |
| Carfilzomib | 23 | 24.6 | 24.7 |
| Doxorubicin | 60 | 21.5 | 21.5 |
| Cytarabine | 41 | 21.2 | 21.2 |
| Amphotericin B | 8 | 18.9 | 19.0 |
| Dasatinib | 22 | 17.9 | 17.9 |
| Vincristine Sulfate | 17 | 17.4 | 17.4 |
| Pegaspargase | 6 | 14.5 | 14.5 |
| Bleomycin Sulfate | 5 | 14.3 | 14.3 |
| Pertuzumab | 13 | 14.3 | 14.3 |
| Temozolomide | 8 | 11.3 | 11.3 |
| Ixazomib | 6 | 6.2 | 6.2 |
| Ixekizumab | 7 | 5.6 | 5.6 |